Of note, while Venetoclax did not affect the expression of MCL-1 and B2CL1 in CLL cells, it led to a decrease in Bcl-2 expression to levels similar to GroPIns, which were further decreased in combination treatments (Figure 4D). The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.